Prelude Therapeutics Incorporated
PRLD
$1.00
$0.117313.29%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.00M | 7.00M | 3.00M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.00M | 7.00M | 3.00M | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 7.00M | 7.00M | 3.00M | -- | -- |
| SG&A Expenses | 27.58M | 28.72M | 29.56M | 28.76M | 28.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 146.98M | 146.71M | 146.26M | 142.27M | 137.51M |
| Operating Income | -139.98M | -139.71M | -143.26M | -142.27M | -137.51M |
| Income Before Tax | -127.83M | -127.17M | -131.52M | -129.85M | -125.55M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -127.83 | -127.17 | -131.52 | -129.85 | -125.55 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -127.83M | -127.17M | -131.52M | -129.85M | -125.55M |
| EBIT | -139.98M | -139.71M | -143.26M | -142.27M | -137.51M |
| EBITDA | -138.20M | -137.94M | -141.65M | -140.78M | -136.19M |
| EPS Basic | -1.68 | -1.68 | -1.77 | -1.80 | -1.88 |
| Normalized Basic EPS | -1.05 | -1.05 | -1.11 | -1.13 | -1.18 |
| EPS Diluted | -1.69 | -1.69 | -1.78 | -1.81 | -1.89 |
| Normalized Diluted EPS | -1.05 | -1.05 | -1.11 | -1.13 | -1.18 |
| Average Basic Shares Outstanding | 303.47M | 303.22M | 296.95M | 288.73M | 269.21M |
| Average Diluted Shares Outstanding | 303.47M | 303.22M | 296.95M | 288.73M | 269.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |